Dyadic International, Inc. (DYAI)
| Market Cap | 29.52M |
| Revenue (ttm) | 3.09M |
| Net Income (ttm) | -7.36M |
| Shares Out | 36.44M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,678 |
| Open | 0.850 |
| Previous Close | 0.820 |
| Day's Range | 0.801 - 0.850 |
| 52-Week Range | 0.655 - 1.346 |
| Beta | 1.21 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+270.33%) |
| Earnings Date | May 13, 2026 |
About DYAI
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research a... [Read more]
Financial Performance
In 2025, Dyadic International's revenue was $3.09 million, a decrease of -11.59% compared to the previous year's $3.50 million. Losses were -$7.36 million, 26.8% more than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price target is $3.0.
News
Dyadic International Earnings Call Transcript: Q4 2025
Transitioned to a commercial-stage biotech with new product launches and expanded partnerships, though 2025 revenue declined to $3.09M and net loss widened. Expecting revenue growth in 2026, with cash runway into 2027 and a focus on recurring revenue streams.
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
Commercial launch of AlbuFree™ DX recombinant human albumin by Proliant Health & Biologicals using Dyadic's production platform, with Dyadic eligible to receive a share of profits from product sales E...
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-enginee...
Dyadic International Transcript: Life Sciences Virtual Investor Forum
Transitioning from R&D to commercial operations, the company has launched multiple products in life sciences, food, and bioindustrial markets, leveraging its C1 and Dapibus platforms. Strategic partnerships and direct sales are driving early revenues, with significant growth expected from late 2026 as more products and collaborations mature.
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology co...
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company produc...
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milesto
Dyadic Applied BioSolutions and Proliant Health & Biologicals Announce Commercial Launch of Recombinant Human Albumin
JUPITER, Fla. and ANKENY, Iowa, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing p...
Dyadic Applied BioSolutions Establishes Commercial Partnership to Accelerate Adoption of Dyadic's Recombinant Growth Factors and Media Proteins
JUPITER, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins and enzymes ...
Dyadic International Transcript: IAccess Alpha Virtual MicroCap Conference
A commercial inflection point is underway, with multiple animal-free protein products launching across life sciences, food nutrition, and bio-industrial markets. Strategic partnerships, rapid product development, and a layered revenue model are expected to drive growth and achieve cash flow positivity at a $12 million run rate.
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing precision-engineered, animal-free proteins...
Dyadic International Earnings Call Transcript: Q3 2025
Q3 2025 marked a pivotal shift to commercial operations, with first bulk protein sales, expanded product launches, and global partnerships. Revenue declined year-over-year, but cash position strengthened and product revenue growth is expected in late 2025 and 2026.
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
Completed strategic pivot from R&D focus to commercial focus Rebranded as Dyadic Applied BioSolutions and launched redesigned website to optimize commercial engagement and investor relations Advanced ...
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology com...
Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
JUPITER, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology co...
Dyadic International Transcript: Small-Cap Virtual Conference
A strategic shift to non-therapeutic, high-growth markets is driving rapid commercialization and revenue generation, with validated platforms and key partnerships enabling product launches in life sciences, food, and bioindustrial sectors. Cash flow positivity is targeted by end of 2026, with profitability expected within three years.
Dyadic to Present at Investor Conferences and BPI East
JUPITER, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology c...
Dyadic International Earnings Call Transcript: Q2 2025
Q2 2025 saw revenue more than double year-over-year, driven by milestone and grant income, while net loss narrowed. The company completed a $5.3 million equity raise, advanced commercial launches across life sciences, food, and bioindustrial segments, and targets profitability by end of 2026.
Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
JUPITER, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on the scalable produ...
Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
JUPITER, Fla., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable produ...
UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value,...
Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value,...
Dyadic International, Inc. Announces Proposed Public Offering of Common Stock
JUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value,...
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
JUPITER, Fla.--(BUSINESS WIRE)---- $DYAI #BioSolutions--Dyadic International, Inc. announces strategic rebrand to Dyadic Applied BioSolutions to reflect focus on commercializing non-therapeutic protei...
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets Leadership team realigned in order to enable execution of ancillary protein strategy Dy...